<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>LGMDs on My New Hugo Site</title>
    <link>http://localhost:1313/lgmd/</link>
    <description>Recent content in LGMDs on My New Hugo Site</description>
    <generator>Hugo -- 0.150.1</generator>
    <language>en-us</language>
    <lastBuildDate>Sun, 05 Oct 2025 00:00:00 +0000</lastBuildDate>
    <atom:link href="http://localhost:1313/lgmd/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Damage_symptoms</title>
      <link>http://localhost:1313/lgmd/damage_symptoms/</link>
      <pubDate>Sun, 05 Oct 2025 00:00:00 +0000</pubDate>
      <guid>http://localhost:1313/lgmd/damage_symptoms/</guid>
      <description>&lt;p&gt;Muscle Damage–Associated Symptoms in LGMDR2 / Miyoshi Myopathy (MM)
LGMDR2 (Limb-Girdle Muscular Dystrophy R2) and Miyoshi Myopathy (MM) belong to the spectrum of Dysferlinopathies, which are caused by mutations in the DYSF gene encoding the dysferlin protein. Dysferlin plays a critical role in sarcolemmal repair and vesicle fusion during muscle membrane resealing. Its loss leads to chronic muscle damage, inflammation, and progressive weakness.&lt;/p&gt;
&lt;ol&gt;
&lt;li&gt;Overview of Muscle Damage–Associated Symptoms
&lt;table&gt;
  &lt;thead&gt;
      &lt;tr&gt;
          &lt;th style=&#34;text-align: center&#34;&gt;Category&lt;/th&gt;
          &lt;th style=&#34;text-align: left&#34;&gt;Specific Symptoms&lt;/th&gt;
          &lt;th style=&#34;text-align: left&#34;&gt;Mechanism&lt;/th&gt;
          &lt;th style=&#34;text-align: left&#34;&gt;Comparison with Normal Muscle Damage&lt;/th&gt;
      &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
      &lt;tr&gt;
          &lt;td style=&#34;text-align: center&#34;&gt;Progressive muscle weakness&lt;/td&gt;
          &lt;td style=&#34;text-align: left&#34;&gt;Loss of proximal (LGMDR2) or distal (MM) strength; difficulty climbing stairs, running, or tiptoeing&lt;/td&gt;
          &lt;td style=&#34;text-align: left&#34;&gt;Chronic fiber necrosis and incomplete regeneration; fatty/fibrotic replacement&lt;/td&gt;
          &lt;td style=&#34;text-align: left&#34;&gt;Similar to &amp;rsquo;loss of functional capacity&amp;rsquo; but chronic and irreversible&lt;/td&gt;
      &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;
&lt;/li&gt;
&lt;/ol&gt;
&lt;table style=&#34;border-collapse:collapse;width:100%;&#34;&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&#34;text-align:center;border:1px solid #ddd;padding:8px;&#34;&gt;Category&lt;/th&gt;
      &lt;th style=&#34;text-align:left;border:1px solid #ddd;padding:8px;&#34;&gt;Specific Symptoms&lt;/th&gt;
      &lt;th style=&#34;text-align:left;border:1px solid #ddd;padding:8px;&#34;&gt;Mechanism&lt;/th&gt;
      &lt;th style=&#34;text-align:left;border:1px solid #ddd;padding:8px;&#34;&gt;Comparison with Normal Muscle Damage&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&#34;text-align:center;border:1px solid #ddd;padding:8px;&#34;&gt;Progressive muscle weakness&lt;/td&gt;
      &lt;td style=&#34;text-align:left;border:1px solid #ddd;padding:8px;&#34;&gt;Loss of proximal (LGMDR2) or distal (MM) strength; difficulty climbing stairs, running, or tiptoeing&lt;/td&gt;
      &lt;td style=&#34;text-align:left;border:1px solid #ddd;padding:8px;&#34;&gt;Chronic fiber necrosis and incomplete regeneration; fatty/fibrotic replacement&lt;/td&gt;
      &lt;td style=&#34;text-align:left;border:1px solid #ddd;padding:8px;&#34;&gt;Similar to ‘loss of functional capacity’ but chronic and irreversible&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;</description>
    </item>
    <item>
      <title>Try to review LGMDR2/MM</title>
      <link>http://localhost:1313/lgmd/first/</link>
      <pubDate>Tue, 30 Sep 2025 21:31:10 -0400</pubDate>
      <guid>http://localhost:1313/lgmd/first/</guid>
      <description></description>
    </item>
  </channel>
</rss>
